stocknshares BioCardia ( NASDAQ: BCDA ) said it has been granted a US patent related to its radial and transendocardial delivery catheter technology. The patent, which expires in 2036, relates to “medical methods and systems suitable for substance delivery to the heart via a radial artery and for the intracardiac delivery of cellular aggregates and other agglomerated materials,” the company said. BioCardia added that its Helix system is the only known system “with patented designs that can enable radial transendocardial biotherapeutic delivery.
” More on BioCardia BioCardia, Inc. (BCDA) Q1 2024 Earnings Call Transcript BioCardia, Inc. (BCDA) Q4 2023 Earnings Call Transcript BioCardia intends to effect reverse stock split BioCardia spikes after Medicare coverage for cell therapy trial Financial information for BioCardia.